.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

ASH 2024: Global Updates in the Management of Chronic Lymphocytic Leukemia

Join leading global experts as they discuss the latest research and treatment advancements in CLL from the ASH 2024 Annual Meeting. Moderated by Dr. John Seymour, this peer exchange features in-depth insights from top clinicians across Europe.

EP. 1: Recent Guideline Updates in the Frontline Management of CLL

January 6th 2025

Dr Niemann provides an overview of the evolving treatment landscape of CLL.

EP. 2: Tailoring Treatment Approaches for Fit vs Unfit CLL Patients

January 8th 2025

A panel of medical experts continues their discussion surrounding an array of treatment options for CLL.

EP. 3: Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL Patients

January 15th 2025

A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.

EP. 4: Time-Limited Therapy with Venetoclax-Obinutuzumab: Rationale and Data

January 24th 2025

Panelists discuss, role of time-limited therapy with venetoclax-obi in this setting, highlighting the underlying rationale and data supporting this approach.

EP. 5: Clinical Insights and Real-World Evidence

January 24th 2025

Panelists discuss, which patients are favored for the Venetoclax-Obinutuzumab treatment approach.

EP. 6: Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines

January 27th 2025

Panelists discuss the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates.

EP. 7: Comparing Venetoclax-Ibrutinib, Venetoclax-Obinutuzumab, and BTKi Options

January 27th 2025

Panelists discuss the role of ven-ibr in patient populations.

EP. 8: Managing CLL with TP53 Mutation or del(17p): Guidelines and Strategies

February 3rd 2025

Panelists review recent ESMO guideline updates for the frontline management of patients with CLL and a TP53 or del(17p) mutation.

EP. 9: Exploring Novel BCL2i and BTKi Combinations in Frontline CLL Therapy

February 3rd 2025

Panelists discuss the ongoing trials evaluating other BCL2i/BTKi combination approaches.

EP. 10: Relapse After Venetoclax-Based Therapy: Early vs Late Management

February 10th 2025

Panelists review recent ESMO guideline updates for managing early relapse after venetoclax-based time-limited therapy, managing relapse after chemoimmunotherapy or late relapse after venetoclax-based time-limited therapy and defining early versus late relapse.